Your browser doesn't support javascript.
loading
Keeping an Eye Out for Immunotherapy Toxicity: A Case of Unilateral Ptosis Caused by Ipilimumab/Nivolumab Therapy.
Jazieh, Khalid; Kottschade, Lisa; Dimou, Anastasios.
Afiliación
  • Jazieh K; Division of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Kottschade L; Division of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Dimou A; Division of Oncology, Mayo Clinic, Rochester, MN, USA.
J Immunother Precis Oncol ; 7(2): 126-129, 2024 May.
Article en En | MEDLINE | ID: mdl-38721405
ABSTRACT
Despite ocular adverse events from immune checkpoint inhibitors being uncommon, they are still important complications to be aware of. We present the case of metastatic melanoma on ipilimumab/nivolumab in a patient who developed immunotherapy complications with delayed diagnosis because the only presenting symptom was unilateral ptosis. We reviewed the literature for relevant and important ocular and neurological complications of immune checkpoint inhibitors.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Immunother Precis Oncol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Immunother Precis Oncol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos